Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

Shen,Xian‑Feng; Zeng,Xian‑Tao; Jian,Zhi‑Yuan; Zhou,Meng; Zhou,Ping; Zhang,Min

doi:10.3892/ol.2015.3723

Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma

Authors:
- Xian‑Feng Shen
- Xian‑Tao Zeng
- Zhi‑Yuan Jian
- Meng Zhou
- Ping Zhou
- Min Zhang
View Affiliations

Affiliations: Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Center for Evidence‑Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: September 18, 2015 https://doi.org/10.3892/ol.2015.3723
Pages: 3199-3205

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between hepatocellular carcinoma (HCC) and the epidermal growth factor (EGF) 61A/G polymorphism has been analyzed in several studies, but results remain inconsistent. Therefore, the aim of the present study was to quantitatively summarize the association between the EGF 61A/G polymorphism and the risk of HCC. The PubMed and EMBASE databases were searched for studies published prior to May 1, 2014. The overall, subgroup and sensitivity analyses were conducted using Comprehensive Meta‑Analysis software, version 2.2. In total, 12 published case‑control studies, consisting of 2,095 patients with HCC and 3,766 control individuals, were included in the present study. Meta‑analysis of the included studies revealed that EGF 61A/G polymorphism contributed to the risk of HCC under all four genetic models, consisting of the G vs. A (OR, 1.25; 95% CI, 1.11‑1.40), GG vs. AA (OR, 1.53; 95% CI, 1.26‑1.85), GG vs. AG + AA (OR, 1.34; 95% CI, 1.13‑1.58) and GG + AG vs. AA (OR, 1.27; 95% CI, 1.08‑1.49) comparisons. Subgroup analysis further suggested that EGF 61A/G polymorphism was associated with the risk of HCC in patients and control individuals with liver disease, based on ethnicity and source of control, respectively. No other significance in residual subgroup analysis was observed. The present meta‑analysis suggests that the EGF 61A/G polymorphism is associated with an increased risk of HCC and may be a potential marker for liver disease, such as hepatitis B virus infection, hepatitis C virus infection and liver cirrhosis.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Di Costanzo GG: Prospective analysis of risk factors for hepatocellular carcinoma on patients with cirrhosis. Hepatology. 38:10612003. View Article : Google Scholar : PubMed/NCBI
3	Thomas MB and Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005. View Article : Google Scholar : PubMed/NCBI
4	Caldwell SH, Crespo DM, Kang HS and Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology. 127(Suppl 1): S97–S103. 2004. View Article : Google Scholar : PubMed/NCBI
5	Yuan JM, Govindarajan S, Arakawa K and Yu MC: Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 101:1009–1017. 2004. View Article : Google Scholar : PubMed/NCBI
6	El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
7	Trevisani F, D'Intino PE, Morselli-Labate AM, et al: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bolondi L, Sofia S, Siringo S, et al: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 48:251–259. 2001. View Article : Google Scholar : PubMed/NCBI
9	Kim CK, Lim JH and Lee WJ: Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 20:99–104. 2001.PubMed/NCBI
10	Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 237:1555–1562. 1962.PubMed/NCBI
11	Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar : PubMed/NCBI
12	Zhang YM, Cao C and Liang K: Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol. 34:150–156. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lanuti M, Liu G, Goodwin JM, et al: A functional epidermal growth factor (EGF) polymorphism, EGF serum levels and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 14:3216–3222. 2008. View Article : Google Scholar : PubMed/NCBI
14	Spindler KL, Nielsen JN, Ornskov D, Brandslund I and Jakobsen A: Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol. 46:1113–1117. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhong JH, You XM, Gong WF, et al: Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One. 7:e321592012. View Article : Google Scholar : PubMed/NCBI
16	Yang Z, Wu Q, Shi Y, Nie Y, Wu K and Fan D: Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: A meta-analysis. Genet Test Mol Biomarkers. 16:1086–1091. 2012. View Article : Google Scholar : PubMed/NCBI
17	Li TF, Ren KW and Liu PF: Meta-analysis of epidermal growth factor polymorphisms and cancer risk: Involving 9,779 cases and 15,932 controls. DNA Cell Biol. 31:568–574. 2012. View Article : Google Scholar : PubMed/NCBI
18	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 151:264–269. 2009. View Article : Google Scholar : PubMed/NCBI
19	Coory MD: Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
20	Egger M, Smith Davey G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
21	Tanabe KK, Lemoine A, Finkelstein DM, et al: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 299:53–60. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yuan JM, Fan Y, Ognjanovic S, et al: Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC Gastroenterol. 13:322013. View Article : Google Scholar : PubMed/NCBI
23	Wu J, Zhang W, Xu A, et al: Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China. Genet Test Mol Biomarkers. 17:595–600. 2013. View Article : Google Scholar : PubMed/NCBI
24	Qi P, Wang H, Chen YM, Sun XJ, Liu Y and Gao CF: No association of EGF 5′UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology. 41:555–560. 2009. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Xie Q, Lu F, et al: Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int. 30:112–118. 2010. View Article : Google Scholar : PubMed/NCBI
26	Chen K, Wei Y, Yang H and Li B: Epidermal growth factor +61 G/A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Genet Test Mol Biomarkers. 15:251–255. 2011. View Article : Google Scholar : PubMed/NCBI
27	Dayyeh Abu BK, Yang M, Fuchs BC, et al: A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 141:141–149. 2011. View Article : Google Scholar : PubMed/NCBI
28	Abbas E, Shaker O, El Aziz Abd G, Ramadan H and Esmat G: Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma: A pilot study. Eur J Gastroenterol Hepatol. 24:458–463. 2012.PubMed/NCBI
29	Borlak J, Meier T, Halter R, Spanel R and Spanel-Borowski K: Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene. 24:1809–1819. 2005. View Article : Google Scholar : PubMed/NCBI
30	Kömüves LG, Feren A, Jones AL and Fodor E: Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 48:821–830. 2000. View Article : Google Scholar : PubMed/NCBI
31	Munafò MR and Flint J: Meta-analysis of genetic association studies. Trends Genet. 20:439–444. 2004. View Article : Google Scholar : PubMed/NCBI
32	Mao M, Zeng XT, Ma T, He W, Zhang C and Zhou J: Interleukin-1α-899 (+4845) C→T polymorphism increases the risk of chronic periodontitis: Evidence from a meta-analysis of 23 case-control studies. Gene. 532:114–119. 2013. View Article : Google Scholar : PubMed/NCBI
33	Leng WD, He MN, Chen QL, Gong H, Zhang L and Zeng XT: Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals. Mol Biol Rep. 40:5987–5992. 2013. View Article : Google Scholar : PubMed/NCBI
34	Zeng X, Zhang Y, Kwong JS, et al: The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: A systematic review. J Evid Based Med. 8:2–10. 2015. View Article : Google Scholar : PubMed/NCBI
35	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI